Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...

Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Shares of Sarepta Therapeutics slumped as much as 49.4% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who ...

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of ...